PCA
BPMC

Pallas Capital Advisors’s Blueprint Medicines BPMC Stock Holding History

Pallas Capital Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-7,361
Closed -$944K – 886
2025
Q2 		$944K Buy
7,361
+518
+8% +$53.8K 0.04% 346
2025
Q1 		$606K Buy
6,843
+1,114
+19% +$109K 0.03% 415
2024
Q4 		$500K Buy
5,729
+72
+1% +$6.59K 0.02% 365
2024
Q3 		$470K Buy
5,657
+176
+3% +$17.5K 0.02% 374
2024
Q2 		$622K Buy
5,481
+252
+5% +$25.2K 0.03% 278
2024
Q1 		$496K Buy
5,229
+32
+0.6% +$2.74K 0.02% 283
2023
Q4 		$479K Sell
5,197
-1,513
-23% -$98K 0.03% 274
2023
Q3 		$365K Hold
6,710
– – 0.02% 271
2023
Q2 		$388K Buy
+6,710
New +$365K 0.02% 212

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Pallas Capital Advisors's BPMC Position: Q3 2025 in Review

Pallas Capital Advisors sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 7,361 shares — an estimated $944K sold.

Pallas Capital Advisors first reported a position in BPMC in Q2 2023 and held it in 9 quarters. The position peaked at $944K in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Pallas Capital Advisors reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Pallas Capital Advisors sold 7,361 Blueprint Medicines shares in Q3 2025, an estimated $944K.
  • Pallas Capital Advisors first reported a position in Blueprint Medicines in Q2 2023 and held it in 9 quarters.
  • Pallas Capital Advisors's Blueprint Medicines position peaked at $944K in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Pallas Capital Advisors's 13F filing for Q3 2025, filed 7 Nov 2025.